The Use of Bone Density Scan in Monitoring Treatment Response in Patients Diagnosed with Osteoporosis: A Retrospective Cohort Study

Table 3

Antiosteoporosis and other medications used among the study group between 2016 and 2019.

Medications	Total	Number (%)
Denosumab	51	No, 26 (51%); Yes, 25 (49%)
Alendronate/cholecalciferol	51	No, 42 (82.4%); Yes, 9 (17.6%)
Alendronate	51	No, 44 (86.3%); Yes, 7 (13.7%)
Teriparatide	51	No, 49 (96.1%); Yes, 2 (3.9%)
Ibandronate	51	No, 49 (96.1%); Yes, 2 (3.9%)
Denosumab	51	No, 50 (98%); Yes, 1 (2%)
Raloxifene	51	No, 50 (98%); Yes, 1 (2%)
Zoledronate	51	No, 50 (98%); Yes, 1 (2%)
No antiosteoporosis drugs	51	No, 40 (78.4%); Yes, 11 (21.6%)
Other medications
Vitamin D supplements	51	No, 14 (27.5%); Yes, 37 (72.5%)
PPIs	51	No, 22 (43.1%); Yes, 29 (56.9%)
Steroids	51	No, 30 (58.8%); Yes, 21 (41.2%)
Antirheumatic drugs	51	No, 42 (82.4%); Yes, 9 (17.6%)
Aromatase inhibitors	51	No, 46 (90.2%); Yes, 5 (9.8%)